What You Should Know:
– Alamar Biosciences, a leader in precision proteomics for early disease detection raises $100M in Series C round, with an additional $28M expected within the next 30 days. This brings their total funding to nearly $250M.
– The Series C funding round was led by led by Sands Capital, with participation from new and existing investors, including both financial and strategic partners. Ian Ratcliffe, Executive Managing Partner at Sands Capital, has joined Alamar’s Board of Directors.
Revolutionizing Early Disease Detection
Alamar’s innovative NULISA technology empowers researchers and clinicians with:
– Unmatched Sensitivity: Utilizing a novel capture and release method, NULISA offers a 10,000-fold improvement in signal-to-noise ratio compared to traditional methods, enabling detection of proteins at incredibly low concentrations (single digit attomolar).
– Enhanced Precision: Coupled with qPCR and NGS readouts, NULISA enables both focused analysis of specific biomarkers and large-scale profiling of hundreds to thousands of proteins, providing a comprehensive picture of disease states.
– Increased Efficiency: The ARGO HT System, launched earlier this year, automates NULISA assays, requiring less than 30 minutes of hands-on time.
Funding Fuels Growth and Innovation
Alamar plans to utilize the funds to:
– Expand its commercial and customer support teams: Ensuring widespread adoption and seamless integration of their technology.
– Drive market adoption: Actively engage with healthcare professionals and researchers to leverage the power of NULISA for early disease detection.
– Develop a wider product portfolio: Offer a diverse range of tools and solutions catered to specific disease areas.
“We are extremely grateful for the strong support we have received from this premium group of investors in this significantly oversubscribed round. It is a testament to our game changing technology, solid IP, and strong early market adoption,” said Dr. Yuling Luo, Founder, Chairman & CEO of Alamar. “Our proprietary NULISA™ technology has demonstrated superior performance and a unique combination of capabilities that will enable our customers to accelerate biomarker discovery and the development of non-invasive tests for diseases with high unmet need. With this funding, we are now well positioned to power precision proteomics through accelerated commercialization.”
